Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
GILD Gilead Sciences, Inc. weekly Stock Chart
GILD [NASD]
Gilead Sciences, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
IndexS&P 500 P/E8.97 EPS (ttm)9.21 Insider Own0.30% Shs Outstand1.30B Perf Week-1.24%
Market Cap107.83B Forward P/E11.01 EPS next Y7.51 Insider Trans-15.39% Shs Float1.30B Perf Month13.83%
Income12.21B PEG- EPS next Q2.12 Inst Own77.50% Short Float1.43% Perf Quarter22.43%
Sales28.47B P/S3.79 EPS this Y-16.50% Inst Trans0.61% Short Ratio1.83 Perf Half Y21.83%
Book/sh17.35 P/B4.76 EPS next Y-14.46% ROA21.10% Target Price81.88 Perf Year1.05%
Cash/sh16.17 P/C5.11 EPS next 5Y-8.21% ROE61.90% 52W Range63.76 - 86.27 Perf YTD15.40%
Dividend2.08 P/FCF10.00 EPS past 5Y41.20% ROI31.00% 52W High-4.20% Beta1.17
Dividend %2.52% Quick Ratio3.20 Sales past 5Y29.40% Gross Margin84.90% 52W Low29.61% ATR1.51
Employees9000 Current Ratio3.40 Sales Q/Q-8.20% Oper. Margin57.80% RSI (14)61.68 Volatility1.72% 2.12%
OptionableYes Debt/Eq0.00 EPS Q/Q-9.60% Profit Margin42.90% Rel Volume0.54 Prev Close82.29
ShortableYes LT Debt/Eq1.16 EarningsOct 25 AMC Payout21.30% Avg Volume10.18M Price82.64
Recom2.40 SMA202.49% SMA508.56% SMA20016.59% Volume5,514,801 Change0.43%
Sep-15-17Initiated RBC Capital Mkts Outperform $94
Sep-05-17Reiterated Wells Fargo Market Perform $73 → $81
Aug-31-17Upgrade Argus Hold → Buy
Aug-31-17Resumed William Blair Outperform $87
Jul-11-17Resumed Jefferies Hold
Jun-23-17Initiated Deutsche Bank Buy $79
Mar-09-17Resumed UBS Neutral $118 → $72
Feb-08-17Downgrade Citigroup Buy → Neutral
Nov-14-16Initiated Stifel Buy $100
Nov-08-16Initiated Mizuho Buy $88
Nov-02-16Reiterated RBC Capital Mkts Outperform $95 → $90
Oct-25-16Reiterated Jefferies Buy $93 → $95
Oct-03-16Reiterated RBC Capital Mkts Outperform $105 → $95
Sep-27-16Downgrade Leerink Partners Outperform → Mkt Perform $112 → $94
Sep-12-16Initiated Berenberg Buy $112
Sep-06-16Upgrade Jefferies Hold → Buy
Jul-29-16Downgrade Argus Buy → Hold
Jul-26-16Reiterated RBC Capital Mkts Outperform $120 → $105
Jul-26-16Downgrade Needham Buy → Hold
Jun-01-16Initiated Gabelli & Co Buy $109
Sep-20-17 06:57PM  These Stocks Pay You to Own Them TheStreet.com
Sep-19-17 09:55AM  Should Value Investors Consider Gilead Sciences (GILD) Stock? Zacks
09:46AM  Your first trade for Tuesday, September 19 CNBC
08:07AM  Taking On Exposure to Innovative Biotechnology Stocks Market Realist
07:09AM  Yes, Juno Therapeutics (JUNO) Just Became a Great CAR-T Trade InvestorPlace
06:09AM  Gilead Sciences' Kite Pharma Deal Has Already Paid for Itself -- for Investors Motley Fool
Sep-18-17 05:59PM  "Fast Money" final trades: AMD, INTC and more CNBC Videos
03:07PM  Why Bellicum Pharmaceuticals Stock Is Rising Today Motley Fool
12:36PM  Benefitting from IBBs Lower Expense Ratio Market Realist
11:35AM  Gilead Sciences: Is The Kite Deal Too Little, Too Late? Barrons.com
10:50AM  The IBB Biotechnology ETF: The Drugs You Need? Market Realist
10:30AM  3 Value Stocks for Smart Investors Motley Fool
Sep-17-17 12:17PM  3 Great Income Stocks That Could Double Their Dividends Motley Fool
Sep-15-17 02:21PM  AbbVie's New Hepatitis C Drug Chipping Away At Gilead's Share Investor's Business Daily
11:07AM  After Gilead Sciences, More Biotech M&A? Barrons.com
07:45AM  3 Reasons Why Gilead Sciences Stock Is a Buy Now Motley Fool
06:00AM  3 Dividend Healthcare Stocks Motley Fool
Sep-14-17 06:45PM  Gilead Prices $3 Billion of Senior Unsecured Notes Business Wire
06:18PM  ETFs with exposure to Gilead Sciences, Inc. : September 14, 2017 Capital Cube
11:44AM  Gilead Sciences, Inc. -- Moody's assigns A3 to Gilead's new sr. notes; stable outlook Moody's
08:53AM  Options Traders Expect Huge Moves in Gilead Sciences (GILD) Stock Zacks
Sep-13-17 03:05PM  Gilead Sciences, Inc.'s Best Investment of 2017 (Hint: It Wasn't Kite Pharmaceuticals) Motley Fool
11:44AM  Gilead Sciences, Inc. :GILD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Capital Cube
10:12AM  Gilead: Too Early for Kite Credit? Barrons.com
08:55AM  Short Sellers Hike Bets in Major Biotechs 24/7 Wall St.
07:37AM  Must-Know Recent Developments for Gilead Market Realist
Sep-12-17 03:08PM  Should You Keep Your Portfolio Healthy with Biotech ETFs? Zacks
10:36AM  How Gileads Other Products Performed in 2Q17 Market Realist
09:06AM  How Did Gileads Blockbuster Drug Harvoni Perform in 2Q17? Market Realist
08:03AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
07:38AM  How Gileads HCV Drugs Portfolio Performed in 2Q17 Market Realist
06:18AM  The Zacks Analyst Blog Highlights: Gilead, Oracle, Morgan Stanley, Expedia and Kroger Zacks
06:03AM  3 Stocks for Future Millionaires Motley Fool
Sep-11-17 07:30PM  5 Ways To Play The Biotech Bull Market Oilprice.com
04:02PM  5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition Motley Fool
03:36PM  Top Stock Reports for Gilead, Oracle & Morgan Stanley Zacks
02:20PM  The Move in SPDR S&P Biotech (ETF) (XBI) ETF Is Coming Get on Board InvestorPlace
12:05PM  How Gileads HIV and HBV Portfolios Performed in 2Q17 Market Realist
10:37AM  How Did Gileads Revenue Trend in 2Q17? Market Realist
10:08AM  See what the IHS Markit Score report has to say about Gilead Sciences Inc. Markit
09:33AM  5 Top-Ranked Biotech Stocks to Buy Right Now Zacks
08:36AM  Whats Gilead Sciences Valuation? Market Realist
Sep-10-17 05:00AM  CAR-T Mania: Could Juno Therapeutics Get Acquired Next? Motley Fool
Sep-08-17 03:00PM  Upgrade Confirms Gilead's Price Strength TheStreet.com
12:54PM  Upgrade Confirms Gilead's Price Strength TheStreet.com
08:52AM  Top Ranked Income Stocks to Buy for September 8th Zacks
Sep-07-17 06:28PM  Myth Busting: Trump Trade A Fallacy Forbes
05:52PM  Despite biotech's epic run, these names are still a barga... CNBC Videos
05:10PM  Are These Healthcare Stocks Top Takeover Targets? Motley Fool
02:54PM  Are You Buying Gilead Sciences, Inc. for the Wrong Reason? Motley Fool
01:53PM  Unusual activity in a biotech and a travel stock CNBC Videos
09:00AM  The Trump White House Gave These Mutual Funds a Big Boost Fortune
08:11AM  Alternative Perspectives On The Biotech M&A Environment Forbes
06:04AM  5 Things Gilead Sciences' Management Just Said That You'll Want to Know Motley Fool
Sep-06-17 03:16PM  Here's What Lifted bluebird bio Inc. Stock 40% Higher in August Motley Fool
02:20PM  Why Kite Pharma Soared 64.8% in August Motley Fool
10:43AM  Buy These 5 Large Caps on Extraordinary ROI Potential Zacks
06:00AM  7 Medical Conditions That Will Be Lining Big Pharma's Pockets by 2020 Motley Fool
Sep-05-17 04:01PM  Gilead Sciences to Present at the Morgan Stanley Global Healthcare Conference on Monday, September 11 Business Wire
03:56PM  [$$] 5 Biotechs On Sale That Offer Less Risk Barrons.com
02:26PM  4 Biotech Stocks to Improve Your Portfolio's Health Zacks
09:56AM  The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Activision Blizzard, Intuit, Alexion Pharmaceuticals and Gilead Sciences Zacks
08:53AM  Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better Motley Fool
08:00AM  Biotech Stocks Back in Favor: Will the Rally Continue? Zacks
07:15AM  Why Juno Therapeutics Shares Vaulted 46% Higher in August Motley Fool
Sep-04-17 11:32AM  The Only 2 Biotech Stocks With a Higher Dividend Yield Than the S&P 500 Motley Fool
Sep-03-17 08:33AM  Better Buy: Gilead Sciences, Inc. vs. Johnson & Johnson Motley Fool
07:02AM  Why Gilead Sciences Shares Soared 10.6% in August Motley Fool
Sep-02-17 10:46AM  Vetr Urges Hold On Gilead After Kite Merger Benzinga
10:33AM  3 Biotech Stocks That Skyrocketed This Week Motley Fool
10:20AM  Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition TheStreet.com
Sep-01-17 08:27PM  3 Reasons Gilead Sciences Jumped to Buy Kite Pharma Motley Fool
05:12PM  Gilead Sciences Oncology M&A Strategy Explained Motley Fool
05:00PM  You Reached Retirement: 3 Stocks to Consider Today Motley Fool
04:13PM  Wonder Why Gilead Sciences Bought Kite Pharma? Heres the Answer! Motley Fool
12:48PM  Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods Zacks
10:49AM  Biotech ETFs Remain Bell of the Ball ETF Trends
09:12AM  Fridays Vital Data: Apple Inc. (AAPL), Advanced Micro Devices, Inc. (AMD) and Gilead Sciences, Inc. (GILD) InvestorPlace
09:00AM  Gilead Sciences to Present at Citis 12th Annual Biotech Conference on Wednesday, September 6 Business Wire
12:30AM  [$$] Hopeful News of the Week The Wall Street Journal
Aug-31-17 09:00PM  Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences Motley Fool
07:15PM  [$$] Hopeful News of the Week The Wall Street Journal
06:23PM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Kite Pharma, Inc. - KITE PR Newswire
03:25PM  Could Gilead Sciences Stock Skyrocket 25%? 1 Analyst Thinks So Motley Fool
02:14PM  Novartis CAR-T gene therapy, the first approved by FDA, to cost $475,000 MarketWatch
10:55AM  Gilead Sciences: No, the Novartis Approval Wasn't Good News Barrons.com
09:41AM  Biotech: Back In Vogue Barrons.com
09:08AM  Incyte and Gilead Sciences: S&P 500s Top Gainers on August 30 Market Realist
08:42AM  Biotech Stock Roundup: CAR-T in Focus on Gilead-Kite Deal, Incyte Up on Baricitinib Update Zacks
Aug-30-17 06:50PM  ETF Topper: Biotechnology Stocks Continue to Show Strength Barrons.com +7.25%
06:46PM  Cramer pinpoints the trend that could lead to a surge in ... CNBC Videos
06:33PM  Cramer: This trend could lead to surge in takeovers CNBC Videos
06:32PM  Cramer pinpoints the trend that could lead to a surge in takeovers CNBC
05:26PM  Gilead Sciences Breaks Out TheStreet.com
05:07PM  This is why tech is a better bet than biotech: Technician CNBC Videos
04:57PM  Why Analog Devices, Gilead Sciences, and Universal Display Jumped Today Motley Fool
04:23PM  How Much Can This Biotech Pop After The FDA OKs Its Drug Bid? Investor's Business Daily
02:41PM  [$$] Rise of 'Earnouts' Muddies M&A Waters The Wall Street Journal
01:59PM  Novartis: A New $475,000 Drug Barrons.com
01:54PM  Gilead Sciences Breaks Out TheStreet.com
Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company's products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Washington Robin LEVP, CFOSep 07Option Exercise24.3033,750819,95643,352Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0018,0701,535,950103,477Sep 11 08:35 PM
Washington Robin LEVP, CFOSep 07Sale85.0033,7502,868,7509,602Sep 11 08:35 PM
MARTIN JOHN CExecutive ChairmanSep 01Option Exercise21.5873,3331,582,1593,070,099Sep 06 08:23 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Option Exercise24.9117,250429,611101,488Sep 06 06:56 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 01Sale83.0525,0002,076,18876,488Sep 06 06:56 PM
MARTIN JOHN CExecutive ChairmanSep 01Sale83.1173,3336,094,9922,996,766Sep 06 08:23 PM
Meyers James REVP Worldwide Commercial OpsAug 31Option Exercise21.0060,0001,260,00062,715Sep 05 05:31 PM
Meyers James REVP Worldwide Commercial OpsAug 31Sale83.1960,0004,991,2902,715Sep 05 05:31 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Option Exercise25.9243,1251,117,815134,238Sep 01 05:15 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 30Sale79.0050,0003,950,00084,238Sep 01 05:15 PM
YOUNG KEVINChief Operating OfficerAug 10Option Exercise0.0091007,141Aug 14 06:57 PM
Meyers James REVP Worldwide Commercial OpsAug 10Option Exercise0.0082003,535Aug 14 06:53 PM
MARTIN JOHN CExecutive ChairmanAug 01Option Exercise21.5873,3331,582,1593,199,969Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Option Exercise26.998,625232,789106,113Aug 03 06:58 PM
MARTIN JOHN CExecutive ChairmanAug 01Sale75.8673,3335,562,7773,126,636Aug 03 06:55 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffAug 01Sale75.8815,0001,138,19091,113Aug 03 06:58 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Option Exercise26.9934,500931,155137,488Jul 25 06:53 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 21Sale74.0040,0002,960,00097,488Jul 25 06:53 PM
MARTIN JOHN CExecutive ChairmanJul 03Option Exercise21.5873,3331,582,1593,199,969Jul 06 06:38 PM
MARTIN JOHN CExecutive ChairmanJul 03Sale71.0073,3335,206,8923,126,636Jul 06 06:38 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJul 03Sale71.065,000355,295102,988Jul 06 06:27 PM
MARTIN JOHN CExecutive ChairmanJun 01Option Exercise21.5873,3331,582,1593,273,302Jun 05 06:26 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffJun 01Sale65.025,000325,114107,988Jun 05 06:15 PM
MARTIN JOHN CExecutive ChairmanJun 01Sale65.2473,3334,784,5313,199,969Jun 05 06:26 PM
Cogan John FrancisDirectorMay 09Option Exercise20.7115,000310,57562,562May 11 06:14 PM
Cogan John FrancisDirectorMay 09Sale67.259,943668,66752,619May 11 06:14 PM
MARTIN JOHN CExecutive ChairmanMay 01Option Exercise21.5873,3331,582,1593,199,969May 03 05:42 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMay 01Sale68.315,000341,529112,988May 03 05:41 PM
MARTIN JOHN CExecutive ChairmanMay 01Sale68.3173,3335,009,4293,126,636May 03 05:42 PM
MARTIN JOHN CExecutive ChairmanApr 03Option Exercise21.5873,3331,582,1593,199,969Apr 05 05:29 PM
MARTIN JOHN CExecutive ChairmanApr 03Sale67.1873,3334,926,2873,126,636Apr 05 05:29 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffMar 30Sale67.485,000337,392117,988Apr 03 06:23 PM
MARTIN JOHN CExecutive ChairmanMar 01Option Exercise21.5873,3331,582,1593,199,969Mar 03 06:29 PM
MOORE NICHOLAS GDirectorMar 01Option Exercise0.00173012,055Mar 03 06:03 PM
MARTIN JOHN CExecutive ChairmanMar 01Sale70.3873,3335,161,2063,126,636Mar 03 06:29 PM
WILSON GAYLE EDirectorFeb 23Option Exercise20.7133,350690,512140,836Feb 27 06:29 PM
MILLIGAN JOHN FPresident and CEOFeb 23Option Exercise21.58100,0002,157,5001,165,924Feb 27 06:13 PM
WILSON GAYLE EDirectorFeb 23Sale69.3020,3651,411,374120,471Feb 27 06:29 PM
YOUNG KEVINChief Operating OfficerFeb 10Option Exercise0.0090802,883Feb 14 12:53 PM
MARTIN JOHN CExecutive ChairmanFeb 01Option Exercise21.5873,3331,582,1593,204,429Feb 03 05:25 PM
YOUNG KEVINChief Operating OfficerFeb 01Option Exercise0.0062002,190Feb 03 05:32 PM
MARTIN JOHN CExecutive ChairmanFeb 01Sale72.5773,3335,322,0693,131,096Feb 03 05:25 PM
MARTIN JOHN CExecutive ChairmanJan 03Option Exercise21.5873,3371,582,2463,204,433Jan 05 03:39 PM
MARTIN JOHN CExecutive ChairmanJan 03Sale73.5973,3375,396,9713,131,096Jan 05 03:39 PM
WILSON GAYLE EDirectorDec 01Option Exercise0.002,1470107,486Dec 05 07:59 PM
MARTIN JOHN CExecutive ChairmanDec 01Option Exercise16.40100,0001,639,5003,231,096Dec 05 12:54 PM
MARTIN JOHN CExecutive ChairmanDec 01Sale73.33100,0007,332,8703,131,096Dec 05 12:54 PM
MADIGAN JOHN WDirectorNov 18Option Exercise20.71105,0002,174,025121,761Nov 22 02:45 PM
MADIGAN JOHN WDirectorNov 18Sale74.86105,0007,860,05916,761Nov 22 02:45 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffNov 09Sale79.0010,000790,000122,964Nov 14 01:03 PM
MARTIN JOHN CExecutive ChairmanNov 01Option Exercise16.40100,0001,639,5003,231,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanNov 01Sale73.76100,0007,376,0463,131,096Nov 03 06:10 PM
MARTIN JOHN CExecutive ChairmanOct 03Option Exercise16.40100,0001,639,5003,231,096Oct 05 12:52 PM
MARTIN JOHN CExecutive ChairmanOct 03Sale77.63100,0007,762,9613,131,096Oct 05 12:52 PM
Alton Gregg HEVP Comm&Acs ALA, Corp&Med AffSep 22Sale81.845,000409,220132,964Sep 26 04:54 PM
open in yahoo | open in reuters | open in google